Answers are grounded in this paper and cite their sources.
To compare hormonal and metabolic profiles in women with polycystic ovary syndrome (PCOS) and hypothalamic-pituitary-ovarian dysfunction (HPOD), with particular emphasis on kisspeptin and ghrelin concentrations and on PCOS subsets characterized by hyperandrogenemia (HA), insulin resistance (IR), and obesity. The prospective study involved women aged 18–45 with menstrual irregularities. Participants underwent gynecological evaluations, including pelvic ultrasound, and biochemical serum analyses to assess hormonal and metabolic parameters. Kisspeptin ( p = 0.003) and ghrelin ( p = 0.006) concentrations were significantly higher in PCOS than in HPOD. Distinct hormonal and metabolic profiles characterized PCOS, HPOD, and PCOS phenotypes. In PCOS, kisspeptin concentrations were higher in women with IR ( p < 0.001) and HA ( p = 0.003), whereas ghrelin concentrations did not differ by IR ( p = 0.611) or HA ( p = 0.153). Neither kisspeptin ( p = 0.428) nor ghrelin ( p = 0.240) differed by BMI category. Kisspeptin concentrations were positively correlated with ghrelin, thyroid-stimulating hormone, IR indices, C-reactive protein, and interleukin-6, and negatively with sex hormone-binding globulin and free thyroxine (all p < 0.05). Ghrelin concentrations positively correlated with dehydroepiandrosterone sulfate and negatively with free thyroxine (all p < 0.05). There were fewer significant correlations in HPOD. In multiple regression, ln(IL-6) was an independent positive predictor of ln(kisspeptin) (β = 0.296, p = 0.027) and fT4 a negative predictor (β=−0.059, p = 0.027), while for ln(ghrelin) only 17-OH-progesterone remained a positive independent predictor (β = 0.042, p = 0.019), with metabolic markers losing significance. The lack of classical PCOS markers as independent predictors suggests that kisspeptin and ghrelin are regulated by primary inflammatory, thyroidal, and steroidogenic axes, with kisspeptin appearing inflammation-sensitive and ghrelin steroidogenesis-related, supporting a multi-axial model of PCOS. ClinicalTrials.gov(NCT06793098), on January 20, 2025.
No takes yet. Share an insight, caveat, or question.
Brodowicz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: